Jasper Therapeutics (JSPR)
(Real Time Quote from BATS)
$23.70 USD
+0.73 (3.18%)
Updated Sep 18, 2024 10:42 AM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Price, Consensus and EPS Surprise
JSPR 23.70 +0.73(3.18%)
Will JSPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for JSPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JSPR
Jasper Therapeutics (JSPR) Upgraded to Buy: Here's What You Should Know
Jasper Therapeutics (JSPR) Is a Great Choice for 'Trend' Investors, Here's Why
JSPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jasper Therapeutics, Inc. (JSPR) Is Up 24.77% in One Week: What You Should Know
Here's Why Momentum in Jasper Therapeutics, Inc. (JSPR) Should Keep going
Here's What Could Help Jasper Therapeutics, Inc. (JSPR) Maintain Its Recent Price Strength
Other News for JSPR
Jasper announces Health Canada clearance of trial application of briquilimab
Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma
Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences
Jasper Therapeutics (JSPR) Gets a Buy from Stifel Nicolaus
Jasper Therapeutics price target lowered by $2 at RBC Capital, here's why